News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
708,063 Results
Type
Article (46216)
Company Profile (336)
Press Release (661511)
Section
Business (209027)
Career Advice (2172)
Deals (35986)
Drug Delivery (103)
Drug Development (82191)
Employer Resources (187)
FDA (16274)
Job Trends (15204)
News (352175)
Policy (33162)
Tag
Academia (2721)
Alliances (50660)
Alzheimer's disease (1269)
Approvals (16199)
Artificial intelligence (144)
Bankruptcy (357)
Best Places to Work (11729)
Biotechnology (231)
Breast cancer (123)
Cancer (1106)
Cardiovascular disease (100)
Career advice (1819)
Cell therapy (248)
Clinical research (65030)
Collaboration (401)
Compensation (198)
COVID-19 (2610)
C-suite (99)
Data (1125)
Diabetes (154)
Diagnostics (6294)
Earnings (85700)
Employer resources (161)
Events (113008)
Executive appointments (315)
FDA (16814)
Funding (359)
Gene therapy (189)
GLP-1 (623)
Government (4478)
Healthcare (19054)
Infectious disease (2698)
Inflammatory bowel disease (111)
Interviews (341)
IPO (16521)
Job creations (3837)
Job search strategy (1565)
Layoffs (434)
Legal (8012)
Lung cancer (177)
Manufacturing (185)
Medical device (13335)
Medtech (13340)
Mergers & acquisitions (19537)
Metabolic disorders (424)
Neuroscience (1558)
NextGen Class of 2024 (6705)
Non-profit (4633)
Northern California (1488)
Obesity (249)
Opinion (198)
Patents (105)
People (58253)
Phase I (20201)
Phase II (28642)
Phase III (21344)
Pipeline (457)
Postmarket research (2633)
Preclinical (8821)
Radiopharmaceuticals (242)
Rare diseases (223)
Real estate (6212)
Regulatory (21969)
Research institute (2467)
Resumes & cover letters (374)
Southern California (1308)
Startups (3767)
United States (13718)
Vaccines (575)
Weight loss (186)
Date
Today (136)
Last 7 days (794)
Last 30 days (3815)
Last 365 days (36409)
2024 (33397)
2023 (40874)
2022 (51938)
2021 (56514)
2020 (54930)
2019 (47667)
2018 (35957)
2017 (33111)
2016 (32695)
2015 (38792)
2014 (32401)
2013 (27552)
2012 (29823)
2011 (30561)
2010 (29055)
Location
Africa (788)
Arizona (201)
Asia (38820)
Australia (6390)
California (3363)
Canada (1291)
China (251)
Colorado (150)
Connecticut (153)
Europe (84243)
Florida (459)
Georgia (124)
Illinois (357)
Indiana (203)
Kansas (98)
Maryland (589)
Massachusetts (2651)
Michigan (170)
Minnesota (288)
New Jersey (969)
New York (971)
North Carolina (737)
Northern California (1488)
Ohio (140)
Pennsylvania (850)
South America (1167)
Southern California (1308)
Texas (468)
Utah (92)
Washington State (365)
708,063 Results for "gb sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 DataCall scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET
Annexon, Inc. today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data.
June 3, 2024
·
1 min read
Drug Development
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1211, Galecto’s first-in-class, oral small molecule galectin-3 inhibitor candidate, at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, USA.
May 1, 2024
·
7 min read
Policy
Cepheid Receives FDA Clearance for Xpert® Xpress GBS
Cepheid announced that it has received clearance from the U.S. Food and Drug Administration for Xpert® Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus.
March 11, 2024
·
3 min read
Job Creations
Massachusetts Increases Life Sciences Investment by $500M Over 10 Years
Massachusetts’ increased investment in the life sciences industry includes boosting its life sciences tax incentive program by $10 million annually, aiding job creation in the state.
November 21, 2024
·
2 min read
·
Angela Gabriel
GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China
Gb Sciences, Inc. has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson’s disease.
March 20, 2023
·
5 min read
Press Releases
Britannia Life Sciences Inc. Announces Results of Annual Meeting of Shareholders
November 14, 2024
·
1 min read
Drug Development
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being developed for maternal administration to protect infants against invasive GBS disease.
July 19, 2023
·
12 min read
Genetown
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease (GD).
September 1, 2023
·
7 min read
Drug Development
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Galecto, Inc. today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis (IPF).
August 15, 2023
·
6 min read
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
1 of 70,807
Next
